Journal of the American Academy of Dermatology · 2019
Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oskardmay Ashley N, Miles J Alex, Sayed Christopher J
Аннотация
BACKGROUND: Few data exist to guide infliximab dosing in hidradenitis suppurativa (HS).
OBJECTIVES: To determine optimal infliximab dosing for patients with HS based on treatment response and achievement of stable dosing.
METHODS: Retrospective cohort study of 52 patients with HS treated with infliximab. Primary outcome was achievement of stable dosing regimen for at least 8 weeks. Secondary outcomes were time to discontinuation, time to titration, changes to inflammatory markers, and clinical response.
RESULTS: Thirty-five patients (67%) achieved stable dosing, most at a schedule of 10 mg/kg every 6 or 8 weeks. At 1 year from initiation, most patients (64%) required dose escalation. Patients tolerated infliximab well and achieved significant improvements in abscess and nodule count, draining sinuses, and erythrocyte sedimentation rate.
LIMITATIONS: Retrospective nature and lack of HS clinical response data for many patients.
CONCLUSIONS: Infliximab 10 mg/kg every 6 or 8 weeks may be a reasonable starting dosage for most patients.
OBJECTIVES: To determine optimal infliximab dosing for patients with HS based on treatment response and achievement of stable dosing.
METHODS: Retrospective cohort study of 52 patients with HS treated with infliximab. Primary outcome was achievement of stable dosing regimen for at least 8 weeks. Secondary outcomes were time to discontinuation, time to titration, changes to inflammatory markers, and clinical response.
RESULTS: Thirty-five patients (67%) achieved stable dosing, most at a schedule of 10 mg/kg every 6 or 8 weeks. At 1 year from initiation, most patients (64%) required dose escalation. Patients tolerated infliximab well and achieved significant improvements in abscess and nodule count, draining sinuses, and erythrocyte sedimentation rate.
LIMITATIONS: Retrospective nature and lack of HS clinical response data for many patients.
CONCLUSIONS: Infliximab 10 mg/kg every 6 or 8 weeks may be a reasonable starting dosage for most patients.